Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504018 | 1.00 | ERN1 (0.42) | ERN1KDM1AKCNH2KDM1BMEN1 | |
| SCHEMBL29471351 | 0.86 | CYP2C9 (0.41) | ERN1KDM1AKCNH2KDM1BMEN1 | |
| SCHEMBL658249 | 0.86 | CYP2C9 (0.41) | ERN1KDM1AKCNH2KDM1BMEN1 | |
| SCHEMBL31438987 | 0.86 | ERN1 (0.40) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL1013026 | 0.86 | ERN1 (0.40) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL1571396 | 0.82 | ERN1 (0.38) | ERN1KDM1AKCNH2KDM1BMEN1 | |
| SCHEMBL12820914 | 0.82 | ERN1 (0.42) | ERN1MEN1ALDH1A1KMT2A | |
| SCHEMBL12353578 | 0.82 | ERN1 (0.42) | ERN1ALDH1A1PRKDC | |
| SCHEMBL19792394 | 0.82 | ERN1 (0.38) | ERN1ALDH1A1PRKDC | |
| SCHEMBL20177010 | 0.82 | ERN1 (0.38) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486281-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-12365682-B2 | Process to make GLP1 RA and intermediates therefor | ELI LILLY AND COMPANY (US) | 2025-07-22 | — | — | US | disclosed |
| WO-2025062334-A1 | 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZENESULFONAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER | BEIGENE SWITZERLAND GMBH (CH) | 2025-03-27 | — | — | WO | disclosed |
| US-20250042899-A1 | PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-06 | — | — | US | disclosed |
| WO-2024137426-A1 | PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR | ELI LILLY AND COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137426-A1 | PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR | ELI LILLY AND COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-114957212-B | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-114957212-A | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | 细胞基因公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220213115-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2022-07-07 | — | — | US | disclosed |
| US-11306101-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| EP-2298747-B1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2016-12-28 | — | — | EP | disclosed |
| WO-2016191366-A1 | MODULATORS FOR NICOTINIC ACETYLCHOLINE RECEPTOR α2 AND α4 SUBUNITS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-01 | — | — | WO | disclosed |
| US-9464076-B2 | Benzothiophene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-2975037-A1 | BENZOTHIOPHENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| WO-2013005157-A1 | SULFONE DERIVATIVES AND THEIR USE AS PKM2 MODULATORS FOR THE TREATMENT OF CANCER | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013005157-A1 | SULFONE DERIVATIVES AND THEIR USE AS PKM2 MODULATORS FOR THE TREATMENT OF CANCER | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2298747-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365682-B2 | Process to make GLP1 RA and intermediates therefor | GLP1R, GIPR, NPY4R | ERN1 2944/4885KDM1A 441/4885KCNH2 1575/4885 |
| US-20160024060-A1 | BENZOTHIOPHENE DERIVATIVE | PDE10A, PDE5A, PDE3B | ERN1 3765/4885KDM1A 2419/4885KCNH2 1372/4885 |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | ERN1 1554/4885KDM1A 2400/4885KCNH2 1893/4885 |
| US-20220213115-A1 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CPT1A, GOT2, IDH2 | ERN1 3300/4885KDM1A 547/4885KCNH2 673/4885 |
| US-20250042899-A1 | PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR | GLP1R, GIPR, NPY4R | ERN1 2944/4885KDM1A 441/4885KCNH2 1575/4885 |
| US-11306101-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CPT1A, GOT2, IDH2 | ERN1 3300/4885KDM1A 547/4885KCNH2 673/4885 |
| US-12486281-B2 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | CPT1A, GOT2, IDH2 | ERN1 3300/4885KDM1A 547/4885KCNH2 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.